UY30600A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
UY30600A1
UY30600A1 UY30600A UY30600A UY30600A1 UY 30600 A1 UY30600 A1 UY 30600A1 UY 30600 A UY30600 A UY 30600A UY 30600 A UY30600 A UY 30600A UY 30600 A1 UY30600 A1 UY 30600A1
Authority
UY
Uruguay
Prior art keywords
new compounds
compounds
relates
activity
inhibitors
Prior art date
Application number
UY30600A
Other languages
English (en)
Spanish (es)
Inventor
Caroline Whitworth
John Martin Pritchard
Jeremy John Payne
John Liddle
Michael John Johnston
Duncan Stuart Holmes
Heather Hobbs
Paul Faulder
Richard Peter Charles Cousins
Sebastien Andre Campos
Michael David Barker
Paul Bamborough
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618776A external-priority patent/GB0618776D0/en
Priority claimed from GB0704012A external-priority patent/GB0704012D0/en
Priority claimed from GB0717170A external-priority patent/GB0717170D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY30600A1 publication Critical patent/UY30600A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
UY30600A 2006-09-22 2007-09-20 Compuestos novedosos UY30600A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0618776A GB0618776D0 (en) 2006-09-22 2006-09-22 Novel compounds
GB0704012A GB0704012D0 (en) 2007-03-01 2007-03-01 Novel compounds
GB0717170A GB0717170D0 (en) 2007-09-04 2007-09-04 Novelcompounds

Publications (1)

Publication Number Publication Date
UY30600A1 true UY30600A1 (es) 2008-05-02

Family

ID=39092148

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30600A UY30600A1 (es) 2006-09-22 2007-09-20 Compuestos novedosos

Country Status (11)

Country Link
US (3) US20100035917A1 (enExample)
EP (1) EP2069341B1 (enExample)
JP (1) JP2010504301A (enExample)
AR (1) AR062928A1 (enExample)
AT (1) ATE493411T1 (enExample)
CL (1) CL2007002708A1 (enExample)
DE (1) DE602007011645D1 (enExample)
PE (1) PE20080925A1 (enExample)
TW (1) TW200836724A (enExample)
UY (1) UY30600A1 (enExample)
WO (1) WO2008034860A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PE20060373A1 (es) * 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0804591D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8877742B2 (en) 2011-06-10 2014-11-04 Glaxosmithkline Intellectual Property Limited Compounds
HUE042374T2 (hu) 2012-06-13 2019-06-28 Incyte Holdings Corp Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
UY35419A (es) * 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
BR112015023356A2 (pt) * 2013-03-14 2017-07-18 Abbvie Inc inibidores de quinase pirrol[2,3-b]piridina cdk9
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN114210133B (zh) * 2021-12-13 2023-01-24 广德辉龙环保科技有限公司 一种抗紫外线过滤袋及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212613A (pt) * 2001-09-19 2004-08-31 Pharmacia Corp Compostos de indazol substituìdos para o tratamento de inflamação
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR062928A1 (es) 2008-12-17
PE20080925A1 (es) 2008-09-04
EP2069341B1 (en) 2010-12-29
JP2010504301A (ja) 2010-02-12
WO2008034860A1 (en) 2008-03-27
TW200836724A (en) 2008-09-16
DE602007011645D1 (de) 2011-02-10
US20080176891A1 (en) 2008-07-24
EP2069341A1 (en) 2009-06-17
ATE493411T1 (de) 2011-01-15
CL2007002708A1 (es) 2008-04-04
US20100035917A1 (en) 2010-02-11
US20080146606A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
UY30600A1 (es) Compuestos novedosos
CO6390057A2 (es) Indazoles oxazol sustituidos como inhibidores de pi3-quinasa
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
NI201000059A (es) Inhibidores de la cinasa c-fms.
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
DE602008000754D1 (de) Tropanverbindungen
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2019010602A (es) Inhibidores de cdk.
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
AR059027A1 (es) Administracion de inhibidores de dipeptidil peptidasa
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
UY30500A1 (es) Compuestos de azabencimidazolilo
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
CR10027A (es) Nuevos derivados de pirrol fusionado
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
CR20110269A (es) Lactamas como inhibidores de beta secretasa
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
UA107689C2 (xx) ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ
CU24020B1 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
PA8667201A1 (es) Nuevos compuestos farmaceuticos
SV2011003857A (es) Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120606